ASCO ‘26: Bispecifics Vs. ADCs, a ‘RAS’ Revolution and a Step Change in Prostate Cancer

Why It Matters

The data could shift first‑line therapeutic choices, expand market opportunities for biotech firms, and accelerate adoption of novel modalities that promise higher efficacy with manageable toxicity.

Key Takeaways

• Merck’s sac‑TMT ADC shows lung inflammation, raising safety concerns
• Ivonescimab bispecific paired with immunotherapy shows lower toxicity
• Daraxonrasib nearly doubles pancreatic cancer survival in Phase 3
• Erleada plus hormone therapy reduces prostate cancer progression risk 20%

Pulse Analysis

The head‑to‑head presentation of Merck’s sac‑TMT ADC and Akeso’s bispecific ivonescimab at ASCO underscored a pivotal debate in non‑small cell lung cancer. While ADCs deliver cytotoxic payloads directly to tumor cells, they can trigger organ‑specific toxicities such as pneumonitis and stomatitis, requiring proactive management. In contrast, bispecific antibodies like ivonescimab, when combined with checkpoint inhibitors, appear to add modest toxicity while delivering notable efficacy gains. Investors are watching closely as Phase 3 outcomes could dictate whether the market leans toward precision‑chemotherapy platforms or next‑generation immune‑engaging biologics.

Revolution Medicines’ daraxonrasib marked a watershed moment for RAS‑driven oncology. By targeting the KRAS G12D mutation, the drug achieved an almost two‑fold increase in median overall survival for patients with advanced pancreatic cancer—a disease where few options exist. The trial’s striking survival curve has ignited a wave of RAS‑focused programs from industry giants such as Roche, Eli Lilly, and Amgen, turning a once‑undruggable target into a burgeoning therapeutic arena. The rapid expansion of RAS inhibitors promises to reshape drug pipelines and may soon extend beyond pancreatic disease to other KRAS‑mutant malignancies.

In prostate cancer, Johnson & Johnson’s PROTEUS trial positioned Erleada as a potential game‑changer for high‑risk patients undergoing surgery. By integrating the androgen‑receptor inhibitor with neoadjuvant and adjuvant hormone therapy, the regimen slashed progression risk by 20 % and made complete pathological responses nine times more likely. Although the combination raised rates of rash and other adverse events, the clinical benefit could broaden Erleada’s addressable market beyond its current advanced‑disease indications, where it already generated $3.5 billion in 2025 revenue and $949 million in Q1 2026. The key challenge now lies in convincing urologists to adopt the earlier‑stage protocol, a shift that could drive substantial incremental sales for J&J.